Vir Biotechnology Inc. (VIR)
Vir Biotechnology Statistics
Share Statistics
Vir Biotechnology has 137.14M shares outstanding. The number of shares has increased by 1.99% in one year.
| Shares Outstanding | 137.14M |
| Shares Change (YoY) | 1.99% |
| Shares Change (QoQ) | 0.79% |
| Owned by Institutions (%) | 64.98% |
| Shares Floating | 87.38M |
| Failed to Deliver (FTD) Shares | 85.86K |
| FTD / Avg. Volume | 4.11% |
Short Selling Information
The latest short interest is 7.86M, so 5.7% of the outstanding shares have been sold short.
| Short Interest | 7.86M |
| Short % of Shares Out | 5.7% |
| Short % of Float | 8.96% |
| Short Ratio (days to cover) | 2.19 |
Valuation Ratios
The PE ratio is -1.92 and the forward PE ratio is -2.83. Vir Biotechnology's PEG ratio is 0.12.
| PE Ratio | -1.92 |
| Forward PE | -2.83 |
| PS Ratio | 13.48 |
| Forward PS | 1.2 |
| PB Ratio | 0.87 |
| P/FCF Ratio | -2.2 |
| PEG Ratio | 0.12 |
Enterprise Valuation
Vir Biotechnology Inc. has an Enterprise Value (EV) of 1.22B.
| EV / Earnings | -2.34 |
| EV / Sales | 16.43 |
| EV / EBITDA | -2.27 |
| EV / EBIT | -2.08 |
| EV / FCF | -2.69 |
Financial Position
The company has a current ratio of 8.71, with a Debt / Equity ratio of 0.08.
| Current Ratio | 8.71 |
| Quick Ratio | 8.71 |
| Debt / Equity | 0.08 |
| Total Debt / Capitalization | 7.27 |
| Cash Flow / Debt | -4.95 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.45% and return on capital (ROIC) is -47.23%.
| Return on Equity (ROE) | -0.45% |
| Return on Assets (ROA) | -0.37% |
| Return on Capital (ROIC) | -47.23% |
| Revenue Per Employee | $181,875 |
| Profits Per Employee | $-1,279,313.73 |
| Employee Count | 408 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1.15M |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -34.06% in the last 52 weeks. The beta is 1.17, so Vir Biotechnology's price volatility has been higher than the market average.
| Beta | 1.17 |
| 52-Week Price Change | -34.06% |
| 50-Day Moving Average | 8.89 |
| 200-Day Moving Average | 8.57 |
| Relative Strength Index (RSI) | 31.69 |
| Average Volume (20 Days) | 2.09M |
Income Statement
In the last 12 months, Vir Biotechnology had revenue of 74.2M and earned -521.96M in profits. Earnings per share was -3.83.
| Revenue | 74.2M |
| Gross Profit | 73.36M |
| Operating Income | -587.16M |
| Net Income | -521.96M |
| EBITDA | -537.61M |
| EBIT | -587.16M |
| Earnings Per Share (EPS) | -3.83 |
Balance Sheet
The company has 312.33M in cash and 90.14M in debt, giving a net cash position of 222.19M.
| Cash & Cash Equivalents | 312.33M |
| Total Debt | 90.14M |
| Net Cash | 222.19M |
| Retained Earnings | -759.78M |
| Total Assets | 1.4B |
| Working Capital | 922.8M |
Cash Flow
In the last 12 months, operating cash flow was -446.35M and capital expenditures -7.3M, giving a free cash flow of -453.65M.
| Operating Cash Flow | -446.35M |
| Capital Expenditures | -7.3M |
| Free Cash Flow | -453.65M |
| FCF Per Share | -3.33 |
Margins
Gross margin is 98.86%, with operating and profit margins of -791.27% and -703.4%.
| Gross Margin | 98.86% |
| Operating Margin | -791.27% |
| Pretax Margin | -704.95% |
| Profit Margin | -703.4% |
| EBITDA Margin | -724.49% |
| EBIT Margin | -791.27% |
| FCF Margin | -611.35% |
Dividends & Yields
VIR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -57.34% |
| FCF Yield | -49.52% |
Analyst Forecast
The average price target for VIR is $20, which is 199.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $20 |
| Price Target Difference | 199.4% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | 1.08 |
| Piotroski F-Score | 3 |